BeyondSpring annual operating margin
2020
2021
2022
BeyondSpring Operating Margin Growth & History (BYSI)
BeyondSpring's operating margin was −2,756.40% for fiscal 2022.
View full BeyondSpring company overviewBeyondSpring annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2022 | 2022-12-31 | −2,756.40% | +2146.63 pp |
| 2021 | 2021-12-31 | −4,903.03% | +30769.74 pp |
| 2020 | 2020-12-31 | −35,672.78% | — |
BeyondSpring quarterly operating margin
Q1.21
Q2.21
Q3.21
Q4.21
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q4 2021 | 2021-12-31 | −3,104.14% | — |
| Q3 2021 | 2021-09-30 | −5,444.81% | — |
| Q2 2021 | 2021-06-30 | −5,910.95% | — |
| Q1 2021 | 2021-03-31 | −5,153.85% | — |
BeyondSpring operating margin trends
Between the periods ended 2020-12-31 and 2022-12-31, BeyondSpring's operating margin increased from −35,672.78% to −2,756.40%, a change of +32916.38 percentage points. The latest reported quarter, Q4 2021, shows −3,104.14%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BeyondSpring source filings ↗Community posts
BeyondSpring secures Fast Track status and trades China subsidiary for trial funding
BeyondSpring ($BYSI) said the FDA granted Fast Track designation to plinabulin plus docetaxel for a defined previously treated non-squamous lung-cancer population. Separately, it signed an agreement to sell the holding company controlling i ...
